Patent · US Active

Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

US8574573B2 · kind B2 · utility

1Cited by

2References

9Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Jose M. Carballido Herrera · Allschwil, CH
Stefan Härtle · Jesenwang, DE
Christoph Heusser · Oberwil, CH
Ingo Klagge · Schwanau, DE
Andrea Polzer · Munich, DE
Christoph Schwaerzler · La Valette-du-Var, FR
Gabriela Wochnik-Veltrup · Unterschleißheim, DE

Key dates

Filing date	Oct 4, 2011
Grant date	Nov 5, 2013
Priority date	—
Expiry date	Oct 4, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.